Drug Profile
Research programme: Alzheimer's disease therapeutics - Celera Diagnostics/Merck
Latest Information Update: 16 Mar 2010
Price :
$50
*
At a glance
- Originator Celera Diagnostics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 10 Aug 2007 Preclinical development is ongoing
- 01 Jan 2006 Celera Diagnostics has been acquired by Celera Genomics Group
- 07 Sep 2005 Celera and Merck have extended their collaboration in the development of therapeutic and diagnostics products for Alzheimer's disease